CD274 and cancer: Nowadays, checkpoint pathway blockade of programmed cell death ligand 1 (PD‐L1) is a highly promising immunotherapy in a subset of patients with a broad spectrum of cancers that involves activating T lymphocytes and enhancing antitumor immunity (Zou et al., 2016).